Regencell Bioscience Holdings Limited Ordinary Shares (RGC) Stock
NASDAQ · RGC
Key stats
- Market cap
- $2.68B
- Price / Earnings ratio
- -221.6x
- EPS (TTM)
- -$0.02
- Volume
- Loading
- 52-week high
- $69.00
- 52-week low
- $4.51
Source: third-party data provider, as of November 13, 2026
Compare with RGC
Recent news

Business Wire
Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
RGCJune 23, 2026
Business Wire
Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
RGC

Business Wire
RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026
RGCJune 23, 2026
Business Wire
RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026
RGC

Business Wire
Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
RGCJune 22, 2026
Business Wire
Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
RGC

Business Wire
RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
RGCJune 2, 2026
Business Wire
RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
RGC
Technical indicators
- RSI 14
- 37.69
- MACD 12/26/9
- -0.59
- EMA 9 of MACD
- -0.29
- MACD histogram
- -0.29
- SMA 50
- $6.85
- Price below SMA 50
- EMA 50
- $7.03
- Price below EMA 50
- SMA 200
- $16.23
- Price below SMA 200
- EMA 200
- $14.78
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2022
2023
2024
2025
2026
0000
Debt & Balance Sheet
Total assets
Total liabilities
2022
2023
2024
2025
2026
22M14M7M0
Revenue to Profit
2026$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-11.7M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Business Wire
Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
RGCJune 23, 2026
Business Wire
Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
RGC

Business Wire
RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026
RGCJune 23, 2026
Business Wire
RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026
RGC

Business Wire
Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
RGCJune 22, 2026
Business Wire
Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
RGC

Business Wire
RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
RGCJune 2, 2026
Business Wire
RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
RGC

Business Wire
Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights
RGCMay 26, 2026
Business Wire
Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights
RGC

Business Wire
Deadline Alert: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
RGCMay 8, 2026
Business Wire
Deadline Alert: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
RGC

Business Wire
Deadline Approaching: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
RGCMay 7, 2026
Business Wire
Deadline Approaching: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
RGC

Business Wire
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Regencell Bioscience Holdings Limited (RGC) Shareholders To Inquire About Securities Fraud Class Action
RGCMay 6, 2026
Business Wire
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Regencell Bioscience Holdings Limited (RGC) Shareholders To Inquire About Securities Fraud Class Action
RGC

Business Wire
RGC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regencell Bioscience Holdings Securities Lawsuit - Contact Levi & Korsinsky
RGCMay 5, 2026
Business Wire
RGC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regencell Bioscience Holdings Securities Lawsuit - Contact Levi & Korsinsky
RGC

Business Wire
Law Offices of Howard G. Smith Encourages Regencell Bioscience Holdings Limited (RGC) Shareholders To Inquire About Securities Fraud Class Action
RGCMay 5, 2026
Business Wire
Law Offices of Howard G. Smith Encourages Regencell Bioscience Holdings Limited (RGC) Shareholders To Inquire About Securities Fraud Class Action
RGC
About Regencell Bioscience Holdings Limited Ordinary Shares
No description available.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees10
CEOMr. Yat-Gai Au
IPO DateJul 14, 2021
HeadquartersCauseway Bay, Hong Kong
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Yat-Gai Au | Founder, Chairman & CEO | 1973 |
| Ms. Michelle Chan | Financial Controller, CFO & Principal Financial Officer | — |
| Mr. Wai Hong Chung | COO, Chief Strategy Officer & Director | 1978 |
| Ms. Antonia Assang | Senior Vice President of Project Management | — |
| Mr. Yat-Pui Au | Chief Business Officer | 1975 |
Fundamentals
Valuation
Price-to-book value194.28
Profitability
Return on Equity-129.00%
Return on Assets-114.00%
EBITDA$-11.30M
Trading
Average volume389,980
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 37.69
- MACD 12/26/9
- -0.59
- EMA 9 of MACD
- -0.29
- MACD histogram
- -0.29
- SMA 50
- $6.85
- Price below SMA 50
- EMA 50
- $7.03
- Price below EMA 50
- SMA 200
- $16.23
- Price below SMA 200
- EMA 200
- $14.78
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.5 | +37.7 | ||||||||||
| 2022 | +13.6 | +2.2 | -41.7 | -3.3 | +36.2 | -1.1 | -10.6 | -3.6 | +7.7 | -13.3 | +22.4 | -5.2 |
| 2023 | -2.6 | -7.6 | -1.4 | -10.1 | -19.7 | +3.4 | -15.5 | -12.2 | -2.6 | +5.0 | -21.6 | +0.0 |
| 2024 | -8.7 | -14.3 | -29.4 | +40.0 | -29.4 | -25.0 | +212.5 | -17.4 | -11.8 | +21.4 | -19.0 | -23.5 |
| 2025 | -23.1 | +20.0 | +663.6 | +107.9 | +1036.9 | -13.4 | -9.6 | +8.3 | +20.2 | +5.2 | -15.0 | +75.7 |
| 2026 | +21.7 | -7.2 | -2.6 | -13.3 | -17.9 | -74.8 | -23.0 | -10.1 | +13.1 | +6.0 | -16.9 |
Compare stocks
Market cap
$2.68B
-
-
-
Price / Earnings ratio
-221.60
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
389,980
-
-
-
Earnings per share
$-0.02
-
-
-



